Aileron Therapeutics Announces the Initiation of Patient Treatment in its First Clinical Ph1b/2 Trial of ALRN-6924 as a Myelopreservation Agent

Aileron Presents Positive Interim Phase 2a Data for ALRN-6924 in Combination with Pfizer’s Palbociclib at the 2019 Congress of the European Society for Medical Oncology

Aileron to Present Interim Phase 2a Clinical Data for ALRN-6924 in Combination with Pfizer’s IBRANCE® (palbociclib) in Patients with MDM2-Amplified Cancers at the 2019 Congress of the European Society for Medical Oncology

Aileron Therapeutics Announces Management Change

Aileron Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference in New York

Aileron Therapeutics Reports Second Quarter 2019 Financial Results

Aileron Therapeutics to Present at the Canaccord Genuity 39th Annual Growth Conference

Aileron Therapeutics to Report Second Quarter 2019 Financial Results on August 6, 2019

Aileron Therapeutics Announces FDA Acceptance of IND for ALRN-6924 as a Myelopreservation Agent in Patients with p53-mutant Cancer Treated with Chemotherapy

Aileron Therapeutics Strengthens Board of Directors with Appointments of William T. McKee and Josef H. von Rickenbach